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GENERAL INTRODUCTION
Diabetes a health-care burden worldwide
Diabetes has become a worldwide public health problem that affects more than 400 
million people.  Overall, the global prevalence of diabetes in the adult population has 
nearly doubled, from 4.7% in 1980 to 8.5% in 2014, and this rate continues to increase.1 
This is a result of increasing obesity and physical inactivity, aging, population growth, and 
urbanization. As the prevalence of diabetes is increasing worldwide, it is no longer a disease 
of the wealthy. Consequently, the United Nations have decided that diabetes is one of the 
four priority non-communicable diseases (NCDs) to be targeted for action.2 Diabetes and 
the other priority NCDs (cancer, chronic lung diseases and cardiovascular disease (CVD)) are 
responsible for almost 70% of all deaths worldwide. The goal is to decrease the mortality 
rates of these four priority NCDs by 25% by 2025.
  In the Netherlands the number of people currently diagnosed with diabetes is estimated 
to be 1.1 million.3 Taking into account the number of people living with undiagnosed 
diabetes, the number of people living with diabetes is 1.2 million. This represents 1 in 14 
people having diabetes in the Netherlands. Moreover, it was recently calculated that, in 
the Netherlands, for a non-diabetic individual aged 45 years and older the lifetime risk of 
developing diabetes is one in three.4 
Diabetes clinical presentation and risk factors
Diabetes mellitus is a chronic metabolic disease marked by high levels of glucose in the blood 
(hyperglycemia). Hyperglycemia occurs when the pancreas does not secrete enough insulin, 
or when the body is resistant to insulin activity. Insulin is the major regulator of glucose 
metabolism, by stimulating the uptake of glucose by muscles and organs and maintaining 
glucose production from the liver. When a patient becomes insulin resistant, the insulin 
binding to its receptor on the surface of a cell is normal but the insulin signaling within 
the cell is abnormal.5 Insulin resistance is often seen in cells in the liver, skeletal muscle, 
adipose tissue and endothelium. To overcome insulin resistance, the secretion of insulin is 
increased; this is known as compensatory hyperinsulinemia. Diabetes develops when the 
compensatory hyperinsulinemia is unable to maintain normal glucose levels.6 The chronic 
hyperglycemic state leads, over time, to late complications including tissue damage, organ 
dysfunction and ultimately organ failure. The eyes, kidneys, nerves, heart and blood vessels 
are particularly affected by the hyperglycemic state. As a result of the organ complications 
the risk of premature mortality increases.1,6
  Diabetes is usually classified into two types, based on etiologic differences.6 Type 1 
diabetes (5-10% of those with diabetes) is the result of an autoimmune destruction of the 
β-cells of the pancreas, leading to absolute insulin deficiency. Clinical presentation often 
includes symptoms of polyuria, polydipsia, and unexplained weight loss.6 
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Type 2 diabetes (90-95% of those with diabetes) is the result of a relative lack of insulin 
(β-cell dysfunction), insulin resistance, or both. The risk factors for the development of type 
2 diabetes are multifactorial. Ethnicity, family history of diabetes, increasing age, overweight 
and obesity, abdominal obesity, diet and physical inactivity are all contributing factors.1,6-8 
For example, the risk of type 2 diabetes occurs at a lower BMI in Asian populations than in 
Europeans.9 The clinical presentation of type 2 diabetes may be similar to that of type 1 
diabetes, but is often asymptomatic.6 Because hyperglycemia develops progressively, the 
early stage is often not severe enough to lead to overt symptoms. Consequently, type 2 
diabetes is often undiagnosed for several years.10,11
  According to the American Diabetes Association, the criteria for the diagnosis of 
diabetes criteria are fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dL), and/or a random 
plasma glucose ≥11.1 mmol/l (200 mg/dL), and/or a glycated haemoglobin (HbA1c) ≥6.5% 
(≥48 mmol/l).12 A fasting plasma glucose of 5.6 to 7.0 mmol/l (100 to 125 mg/dL), and/or a 
random plasma glucose of 7.8 to 11.0 mmol/l (140 to 199 mg/dL), and/or a HbA1c of 5.7% 
(≥48mmol/l ) to 6.4% (≥48mmol/l ) are defined as prediabetes. People with prediabetes 
should be tested yearly for diabetes.12
Cardiovascular risk factors in diabetes 
Compared with non-diabetic people, people with type 2 diabetes are disproportionately 
affected by CVD, such as myocardial infarction and stroke.13 Hence, the presence of diabetes 
is a major risk factor for CVD and premature mortality. Moreover, people with prediabetes 
are already at an increased risk of CVD.14-16 However, the pathogenesis of CVD in type 2 
diabetes is complex. 
  One risk factor, often mentioned as a possible explanation for the increased cardio-
vascular (CV) risk in diabetes, is the chronic hyperglycemic state. As hyperglycemia is mostly 
asymptomatic, it can remain undiagnosed and consequently untreated for several years. 
During hyperglycemia, proteins or lipids become glycated after exposure to sugars, and 
advanced glycation end products (AGEs) are formed. Also monocyte adhesion to arterial 
endothelial cells is enhanced.11,17 Both processes promote the development of atherosclerosis 
and ultimately CVD.17,18 However, in type 2 diabetes, compared with type 1 diabetes, 
hyperglycemia itself is not a very strong risk factor for CVD. For instance, an increment of 1 
unit (%) of HbA1c increased CV mortality by 52.5% in people with type 1 diabetes, and only 
by 7.5% in people with type 2 diabetes, although the overall mortality rate was similar.19 
Furthermore, CV benefits of intensive glucose-lowering therapy in type 2 diabetes have not 
been unequivocally demonstrated in clinical trials.20-22 In addition, it has been suggested 
that not hyperglycemia but the related insulin resistance is a more important risk factor 
for CVD.10,11 Insulin resistance and the accompanying hyperinsulinemia are both linked to 
an increased CV risk.8,23,24 In addition, insulin resistance is associated with prothrombotic, 
proinflammatory and atherogenic abnormalities such as impaired endothelial function, 
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subclinical inflammation, changes in adipokines, dyslipidemia, increased levels of free fatty 
acids, and changes in mediators of thrombosis and fibrinolysis.8,23,25 For example, people with 
insulin resistance already display endothelial dysfunction and inelastic arteries, indicating 
vascular dysfunction.26 Type 2 diabetes further enhances this vascular dysfunction, resulting 
in a more stiffened artery and a higher risk of CVD.27
 Furthermore, insulin resistance increases due to other CV risk factors, including obesity, 
abdominal obesity, elevated blood pressure, elevated total triglycerides, and low HDL 
cholesterol. For example, abdominal obesity itself causes some degree of insulin resistance 
by changing the secretion of adipokines (cytokines secreted by adipose tissue) like leptin 
and adiponectin.28 Moreover, insulin resistance is triggered by an excess accumulation of 
intracellular triglycerides. Hence, it is not clear whether insulin resistance is a causal factor 
or simply a marker for the increased CV risk. 
  The well-known classic risk factors for CVD, such as hypertension, dyslipidemia and 
cigarette smoking, are significant risk factors of CV mortality in people, both with or without 
diabetes. However, the absolute risk of CV mortality related to every kind or risk factor is at 
least twice as great in people with diabetes as in people without diabetes.29 Therefore, the 
increased CV risk in diabetes cannot be attributed mainly to these classic risk factors.10,11 
Other well-known CVD risk factors include obesity, abdominal obesity and physical 
inactivity, although not every obese person is at high risk of CVD and diabetes.30,31 However, 
abdominal obesity, in particular an excess of intra-abdominal cq visceral adipose tissue, is 
undoubtedly associated with CVD risk.32,33 Nowadays, visceral adipose tissue is recognized 
not only as a storage of lipids but also as an endocrine organ with adipocytes secreting 
bioactive factors and pro-inflammatory cytokines commonly known as adipokines. 
Adipokines promote endothelial dysfunction, insulin resistance, hypercoagulability, and 
ultimately atherosclerosis.33-35 
  Overall, type 2 diabetes is considered to be a low-grade chronic inflammatory disease.36-38 
Moreover, insulin resistance, which is common in type 2 diabetes, is also linked to chronic 
inflammation.39 Atherosclerosis is, like diabetes and insulin resistance, recognized as a 
chronic inflammatory disease.40,41 Therefore, inflammation may be an antecedent of both 
type 2 diabetes and premature atherosclerosis.
DPP-4 a new link between type 2 diabetes and cardiovascular risk?
Although inflammation may precede both type 2 diabetes and premature atherosclerosis, 
the exact interplay between the immune system, the pathophysiology of type 2 diabetes, 
and CVD is not yet fully understood. Recent data suggest a pathophysiological link between 
the enzyme dipeptidyl peptidase 4 (DPP-4), endothelial dysfunction and low-grade chronic 
inflammation, all of which are directly linked to the pathogenesis and clinical manifestations 
of type 2 diabetes and atherosclerosis. 
14
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 DPP-4 (also known as CD26) is an enzyme which can be in soluble form in plasma or 
incorporated into the plasma membrane of many cell types,42 including endothelial cells.43 
In addition, the main endogenous source of DPP-4 is probably the endothelial cell.44 The 
release of DPP-4 from the membrane can be enhanced by stimuli like insulin resistance and 
chronic low-grade inflammation.45-47 DPP-4 activity is increased during hyperglycemia.48 In 
people with drug-naïve type 2 diabetes, compared with healthy controls, DPP-4 activity is 
significantly increased, and it decreases after active glucose control.45 Furthermore, it was 
found that DPP-4 activity independently predicted the risk of developing prediabetes and 
type 2 diabetes in normoglycemic people after 4 years of follow-up.49 DPP-4 rapidly degrades 
incretins such as glucagon-like peptide 1 (GLP-1), which controls glucose dependent insulin 
secretion. GLP-1 has several additional extra-glycemic effects, which have been associated 
with favorable CV effects. However, DPP-4 has several additional effects beyond GLP-1 
degradation.50 
  DPP-4 is widely distributed in tissues such as the kidney, intestines, adipose tissue, 
endothelial cells and bone marrow derived cells.51,52 DPP-4 has been shown to cleave 
multiple substrates, many of which influence the CV system.51,52 One example substrate is the 
chemokine stromal cell-derived factor- 1α (SDF-1α), which is responsible for the recruitment 
of endothelial progenitor cells (EPCs).52 EPCs are known to play a role in vascular repair.53,54 
Moreover, DPP-4 is expressed on blood T cells, when activated cytokines like IL-2, Il-10, IL-12 
and IFN-y are released.45,46,51,55 Therefore, DPP-4 appears to regulate several physiological 
pathways, and not only affecting insulin secretion but also inflammation, immunity, and 
vascular function.46 Considering the higher DPP-4 activity level in people with diabetes as 
compared to non-diabetics, it can therefore be assumed that DPP-4 constitutes a new link 
between type 2 diabetes and CV risk.
  In order to reduce glycemic levels by prolonging the half-life of incretins, DPP-4 
inhibitors (commonly referred to as gliptins) have been developed for the treatment of type 
2 diabetes. Moreover, DPP-4 inhibition has several other effects on physiological pathways, 
which may reduce the CV risk, as shown in Figure 1.
Treatment of diabetes 
The treatment modalities for type 2 diabetes are numerous. Not all risk factors for type 
2 diabetes are modifiable, such as ethnicity and age; however, others like obesity are. 
Therefore, the keys to treatment and prevention of type 2 diabetes are diet and lifestyle 
changes.1,6,10,11 For instance, insulin resistance may improve with weight reduction and 
increased physical activity. However, if hyperglycemia is not satisfactorily controlled by 
diet and lifestyle changes, drugs may be needed. To monitor the treatment of diabetes the 
measurement of HbA1c is the method of choice. HbA1c reflects average glycemia over several 
months and is related to the risk of diabetes complications.56 The glycemic target for adults 
with diabetes is a HbA1c of <7.0% (53 mmol/mol).
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Although this target can be individualized based on the effect and safety of the treatment, 
in which case the target may be more or less stringent.12 For example, severe hypoglycemia, 
which can be a complication of aggressive glycemic control, is a serious side effect that 
should be prevented, particularly in the frail elderly. Therefore, setting higher HbA1c 
control targets is sometimes necessary. This is in contrast to cases of newly diagnosed 
young adults without important comorbidities, for whom more stringent HbA1c control 
targets are determined as optimal.57 Moreover, the United Kingdom Prospective Diabetes 
Study (UKPDS), that included about 5000 recently diagnosed people with type 2 diabetes, 
compared intensive glycemic treatment with conventional treatment. The UKPDS showed a 
long-lasting CV benefit of intensive glycemic control, even after intensive glycemic control 
had relented.58 This benefit, long after treatment given in an early phase of a disease, is 
described as the “legacy effect”. Therefore, achieving glycemic control as soon as possible, 
particularly early in the disease, may account for long-term beneficial CV effects. 
  Currently there are several types of drugs that work in different ways to lower blood 
glucose levels. Ideally, since people with type 2 diabetes suffer from an increased risk of 
CVD, drugs to treat diabetes should, beyond their glycemic effects, also offer CV protection. 
Metformin is recommended in the guidelines as the first line drug of choice because it has 
beneficial effects on insulin resistance. Furthermore, metformin monotherapy has a low risk 
on hypoglycemia, neutral effect on weight, and low costs. If the HbA1c target is not achieved 
after the start of metformin, the start of another antihyperglycemic drug along with 
metformin is recommended. Other treatment options commonly used with metformin are: 
a sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist 
and insulin.57 Compared with the effects of other active-comparator drugs, metformin’s 
beneficial effects on CV events are not unconditional.59 Although metformin is associated 
with a reduction of CV events when compared with placebo or no treatment, the residual 
CV risk is still high.10,11,59 Therefore, other anti-diabetic drugs than metformin should be 
investigated for their greater ability to reduce CV risk. For instance, DPP-4 inhibitors, which 
are a relatively new class of oral anti-diabetic drugs, may have favorable CV effects, as shown 
in Figure 2.51,60 Experimental studies have shown that DPP-4 inhibitors reduce atherosclerotic 
plaque area and macrophage accumulation.51 This is in line with the suggestion that DPP-
4 forms a link between diabetes and CVD. Furthermore, DPP-4 inhibitors are effective in 
reducing HbA1c without inducing hypoglycemia.
51 The CV safety (non-inferiority) of DPP-4 
inhibitors (i.e. alogliptin, saxagliptin, sitagliptin) has been demonstrated in three published 
CV outcome trials (EXAMINE61, SAVOR62, TECOS63), although these trials were unable to 
demonstrate a clear CV benefit. However, these trials were designed to demonstrate CV 
safety, and DPP-4 inhibitors were added to usual care in people with established CVD. 
Nevertheless, randomized controlled trials that investigate the effect of DPP-4 inhibitors on 
favorable CV effects, like reducing atherosclerotic plaque areas, are lacking. 
17
General introduction and aims of the thesis
1
Finally, it may be clear that the increased CV risk in diabetes is the result of the interaction 
of various risk factors, of which hyperglycemia is only one. Therefore, glycemic control is 
not the only treatment target for type 2 diabetes. Treatment of other CV risk factors like 
hypertension and dyslipidemia, lifestyle advice to stop cigarette smoking and to increase 
physical activity and achieve a healthy weight, are treatment targets at least as important 
as hyperglycemia. 
Figure 2 | Effects of DPP-4 inhibitors on cardiovascular risk factors in people with type 2 diabetes. 
Adapted with permission from Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10:73-84.51
Imaging of cardiovascular risk 
The most common underlying process behind CVD is atherosclerosis. Atherosclerosis is 
a process that develops when plaques appear in the arterial wall, narrowing the arteries. 
Rupture of a plaque can cause a myocardial infarction or stroke.64 A plaque prone to rupture 
is defined as high-risk, or also described as a vulnerable plaque.65 Several pathological 
processes such as endothelial dysfunction, inflammation, lipid accumulation, angiogenesis, 
thrombosis, and calcification are involved in the vulnerable plaque, and may also serve as 
markers to predict CVD.66 With conventional morphologic imaging such as B-mode duplex 
ultrasound and computed tomography (CT) angiography, it is possible to identify stenotic 
atherosclerotic lesions, but this imaging does not provide any information about underlying 
vulnerable plaque processes, like arterial inflammation. Nowadays the identification of 
the vulnerable plaque, with novel imaging modality options, is a hot topic. For example, 
positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) is a widely 
used modality for tumor imaging, but is also being used to assess atherosclerosis, and in 
particular inflammation. In addition, high carotid 18F-FDG uptake, as a surrogate of arterial 
18
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inflammation, predicts CVD independent of traditional risk factors in asymptomatic 
people.67 Furthermore, 18F-sodium fluoride (18F-NaF), commonly known as a bone tracer, is a 
promising marker to assess active, early phase microcalcification. 18F-NaF binds to areas of 
microcalcification within an (even non-visibly calcified) atherosclerotic plaque.68 In addition, 
a clinical study showed that ruptured high-risk coronary plaques have significantly higher 
18F-NaF uptake than do low-risk coronary plaques.69
  Another possibility for imaging of CV risk is quantitative assessment of abdominal 
adipose tissue by means of Magnetic Resonance Imaging and CT.70 Visceral abdominal 
adipose tissue (VAT) is a major contributor to CV risk.34,71 It is likely that not only the VAT 
mass but also the metabolic state of VAT, i.e. overproduction of adipokines, is related to CV 
risk.72,73 Consequently, there is a need for a simple but accurate reproducible tool to analyze 
abdominal adipose tissue using a 18F-FDG-PET/CT scan. 
  Finally, other innovative techniques besides imaging modalities may be useful for 
assessing the CV risk in people with diabetes. An example is applanation tonometry, which 
can be non-invasively used to assess aortic pulse wave velocity (PWV). PWV is a marker of 
arterial stiffness and a powerful predictor of CV outcomes in the general population and 
also in patients with diabetes.27,74,75 
AIMS AND OUTLINE OF THE THESIS 
People with type 2 diabetes are at increased risk of CVD because of the interaction of various 
risk factors. Clearly, hyperglycemia is only one part of the picture for increased CV risk. 
Moreover, glycemic control is not the only treatment target of type 2 diabetes; managing 
the CV risk is also an essential target. Obviously, drugs to treat diabetes should, beyond their 
glycemic effects, also offer CV protection. To evaluate treatment effects beyond only the 
glycemic effects, there is a considerable need for CV risk markers that may serve as a readout 
for therapeutic approaches. For the detection of atherosclerosis the well-known CVD risk 
factors provide less specific information than do novel imaging modalities and innovative 
techniques. Therefore, assessment of atherosclerosis and CV risk by using imaging modalities 
and innovative techniques may reveal CV risk markers and provide a readout for therapeutic 
approaches. Moreover, imaging may uncover the mechanisms whereby diabetes increases 
CV risk. 
 The aim of the work presented in this thesis is twofold. Part I focuses on different aspects 
of CV risk imaging. Chapter 2, as part of the introduction, gives an overview of imaging 
modalities and different imaging agents to identify pathophysiological processes occurring 
within the high-risk plaque. Chapter 3 provides more insight into 18F-NaF as a marker of 
microcalcifications in the atherosclerotic plaque. Chapter 4 presents an evaluation of 
19
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the reproducibility and repeatability of a semi-automated method for assessment of the 
metabolic activity represented as 18F-FDG uptake of, especially, VAT on 18F-FDG PET/CT scans. 
 Part II of the thesis deals with the relationship between different CV markers assessed 
by means of imaging modalities and innovative techniques, markers representing different 
stages of atherosclerosis in people with early type 2 diabetes. Chapter 5 discusses the 
relationship between PWV as a measure of arterial stiffness and arterial  18F-FDG uptake 
as a measure of arterial inflammation in people with early type 2 diabetes. Furthermore, 
part II shows the results of a randomized controlled trial with the DPP-4 inhibitor linagliptin 
in early type 2 diabetes, investigating treatment effects beyond their glycemic effects. 
Chapter 6 describes the treatment effects of linagliptin on PWV as a surrogate marker 
of arterial stiffness and early atherosclerosis. Chapter 7 presents the treatment effects of 
linagliptin on arterial 18F-FDG uptake as a measure of arterial inflammation. The final chapter, 
Chapter 8, summarizes the results of this thesis and discusses future perspectives. 
20
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